These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 7902829

  • 1. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K.
    Int J Cancer; 1993 Dec 02; 55(6):963-7. PubMed ID: 7902829
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
    Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV.
    Int J Cancer; 1994 May 15; 57(4):574-80. PubMed ID: 7910153
    [Abstract] [Full Text] [Related]

  • 3. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.
    Prostate; 1997 Aug 01; 32(3):164-72. PubMed ID: 9254895
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992 Aug 01; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 5. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ.
    Br J Cancer; 1994 Nov 01; 70(5):886-92. PubMed ID: 7947094
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T.
    Acta Oncol; 1994 Jan 01; 33(6):693-701. PubMed ID: 7946450
    [Abstract] [Full Text] [Related]

  • 10. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G, Schally AV.
    Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):956-60. PubMed ID: 9023364
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
    Qin Y, Halmos G, Cai RZ, Szoke B, Ertl T, Schally AV.
    J Cancer Res Clin Oncol; 1994 Aug 01; 120(9):519-28. PubMed ID: 8045917
    [Abstract] [Full Text] [Related]

  • 15. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J, Halmos G, Szepeshazi K, Schally AV.
    Cancer; 1993 Dec 01; 72(11):3263-70. PubMed ID: 8242552
    [Abstract] [Full Text] [Related]

  • 16. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K.
    Prostate; 2000 Jul 01; 44(2):172-80. PubMed ID: 10881027
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
    Shirahige Y, Cai RZ, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV.
    Biomed Pharmacother; 1994 Jul 01; 48(10):465-72. PubMed ID: 7858155
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G.
    Cancer; 2000 Mar 15; 88(6):1384-92. PubMed ID: 10717621
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S, Miller G, Schally AV.
    Cancer Res; 1991 Nov 01; 51(21):6006-9. PubMed ID: 1682040
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV.
    Eur J Cancer; 1997 Jun 01; 33(7):1141-8. PubMed ID: 9376196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.